Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

106.02 0.32

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

104.19

Massimo

106.25

Metriche Chiave
By Trading Economics
Entrata	-8.1M -56M
Vendite	2.9M 60M
EPS	-0.83
Margine di Profitto	-92.559
Dipendenti	414
EBITDA	-7.6M -50M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+28.6% upside

Dividendi
By Acuity
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.6B 7.4B
Apertura precedente	105.7
Chiusura precedente	106.02

Notizie sul Sentiment di mercato

By Acuity

67%

33%

298 / 340 Classifica in Healthcare

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

20 lug 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

28.6% in crescita

Previsioni per 12 mesi

Media 137.09 USD 28.6%

Alto 159 USD

Basso 105 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

298 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.